Functionally linked potassium channel activity in cerebral endothelial and smooth muscle cells is compromised in Alzheimer’s disease
Open Access
- 21 June 2022
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (26)
Abstract
The brain microcirculation is increasingly viewed as a potential target for disease-modifying drugs in the treatment of Alzheimer’s disease patients, reflecting a growing appreciation of evidence that cerebral blood flow is compromised in such patients. However, the pathogenic mechanisms in brain resistance arteries underlying blood flow defects have not yet been elucidated. Here we probed the roles of principal vasodilatory pathways in cerebral arteries using the APP23 mouse model of Alzheimer’s disease, in which amyloid precursor protein is increased approximately sevenfold, leading to neuritic plaques and cerebrovascular accumulation of amyloid-β similar to those in patients with Alzheimer’s disease. Pial arteries from APP23 mice (18 mo old) exhibited enhanced pressure-induced (myogenic) constriction because of a profound reduction in ryanodine receptor-mediated, local calcium-release events (“Ca2+sparks”) in arterial smooth muscle cells and a consequent decrease in the activity of large-conductance Ca2+-activated K+(BK) channels. The ability of the endothelial cell inward rectifier K+(Kir2.1) channel to cause dilation was also compromised. Acute application of amyloid-β 1-40 peptide to cerebral arteries from wild-type mice partially recapitulated the BK dysfunction seen in APP23 mice but had no effect on Kir2.1 function. If mirrored in human Alzheimer’s disease, these tandem defects in K+channel-mediated vasodilation could account for the clinical cerebrovascular presentation seen in patients: reduced blood flow and crippled functional hyperemia. These data direct future research toward approaches that reverse this dual vascular channel dysfunction, with the ultimate aim of restoring healthy cerebral blood flow and improving clinical outcomes.Keywords
Funding Information
- British Heart Foundation (FS/19 /8/34163)
- British Heart Foundation (PG/18/7/33535)
- British Heart Foundation (AA/18/4/34221)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01-NS-110656)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01-NS-119971)
- HHS | NIH | National Institute of General Medical Sciences (P20-GM-135007)
- HHS | NIH | National Heart, Lung, and Blood Institute (R35-HL-140027)
- Fondation Leducq (19CVD01)
This publication has 46 references indexed in Scilit:
- L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse modelNeurobiology of Aging, 2015
- Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer’s disease and vascular dementiaBrain, 2015
- Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathologyNature Medicine, 2008
- Spatial Distribution of White-Matter Hyperintensities in Alzheimer Disease, Cerebral Amyloid Angiopathy, and Healthy AgingStroke, 2008
- The sarcoplasmic reticulum and arrhythmogenic calcium releaseCardiovascular Research, 2007
- Enhanced sarcolemmal Ca2+ efflux reduces sarcoplasmic reticulum Ca2+ content and systolic Ca2+ in cardiac hypertrophyCardiovascular Research, 2004
- Alzheimer disease and cerebrovascular pathology: an updateJournal of Neural Transmission, 2002
- Aβ1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activationProceedings of the National Academy of Sciences, 2000
- The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variantNeurology, 1996
- Relaxation of Arterial Smooth Muscle by Calcium SparksScience, 1995